BA-Merrill Lynch 13/11/2009 1 Buy, Medium Risk $38.90 22.7%
The broker notes some conflicting views as to the state of the blood fractionators market implies some risk of a downward shift in prices, reflecting recent increased inventory levels in the wholesaling market.
There are no changes to its forecasts or rating, the broker merely highlighting this as an issue to watch in coming weeks/months.
latest rating, page-45
Add CSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$301.50 |
Change
3.840(1.29%) |
Mkt cap ! $145.6B | |||
| Open | High | Low | Value | Volume |
| $300.00 | $301.98 | $299.34 | $91.91M | 305.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 48 | $301.49 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $301.51 | 40 | 14 |
View Market Depth
| Last trade - 14.40pm 11/07/2024 (20 minute delay) ? |
| CSL (ASX) Chart |